Merck looks to ditch the needles with its next-gen oral PCSK9 inhibitor for high cholesterol

[cafead]

via The pharma giant unveiled on Monday what it says are the first in-human results for an oral PCSK9 inhibitor. The candidate, MK-0616, was well-tolerated in men and women with high cholesterol at doses up to 300 mg, with no deaths or serious side effects, the company said at the American Heart Association conference.

article source